New Materials for Stem Cell Transplants to Treat Type 1 Diabetes
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION
This project is creating special materials to help stem cells grow into healthy insulin-producing cells and protect them from the immune system for people with Type 1 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11158741 on NIH RePORTER |
What this research studies
Type 1 diabetes happens when the body's immune system destroys the cells that make insulin. While insulin shots help, they can be difficult to manage and don't always prevent long-term problems. This project aims to find a better way by using stem cells, which can be grown into new insulin-producing cells. Researchers are developing special materials that will help these new cells mature properly and protect them from being attacked by the immune system. The goal is to allow these transplanted cells to work effectively without the need for strong medications that suppress the immune system.
Who could benefit from this research
Good fit: This research is foundational for future treatments for individuals with Type 1 diabetes, including both children and adults.
Not a fit: Patients without Type 1 diabetes or those whose diabetes is not caused by β-cell destruction would not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to a new treatment for Type 1 diabetes that replaces damaged cells and reduces or eliminates the need for daily insulin injections and lifelong immunosuppression.
How similar studies have performed: While cadaveric islet transplantation has shown success in restoring insulin production, this approach with stem cells and biomaterials to avoid immunosuppression is a novel and largely untested strategy.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Garcia, Andres J — Georgia Institute of Technology
- Study coordinator: Garcia, Andres J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.